REGγ is a strong candidate for the regulation of cell cycle, proliferation and the invasion by poorly differentiated thyroid carcinoma cells

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 5, 2012, Pages 459-465

  Zhang, M ^a   Gan, L ^a   Ren, G S ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Cell proliferation; PDTC; REG ; SW579 cell line; Thyroid carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; PROTEIN P21; PROTEIN P27; PROTEINASE; REG GAMMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL INVASION; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; POORLY DIFFERENTIATED THYROID CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84861151349     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500035     Document Type: Article

References (38)

1. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426: 895-899.
2. Varshavsky A. Regulated protein degradation. Trends Biochem Sci 2005; 30: 283-286.
3. Dubiel W, Pratt G, Ferrell K, Rechsteiner M. Purification of an 11 S regulator of the multicatalytic protease. J Biol Chem 1992; 267: 22369-22377.
4. Ma CP, Slaughter CA, DeMartino GN. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J Biol Chem 1992; 267: 10515-10523.
5. Realini C, Jensen CC, Zhang Z, Johnston SC, Knowlton JR, Hill CP, et al. Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. J Biol Chem 1997: 272: 25483-25492.
6. Masson P, Andersson O, Petersen UM, Young P. Identification and characterization of a Drosophila nuclear proteasome regulator. A homolog of human 11 S REGgamma (PA28gamma). J Biol Chem 2001; 276: 1383-1390.
7. Wojcik C, Tanaka K, Paweletz N, Naab U, Wilk S. Proteasome activator (PA28) subunits, alpha, beta and gamma (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells. Eur J Cell Biol 1998; 77: 151-160.
8. Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, et al. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 1996; 381: 166-168.
9. Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitinand ATP-independent manner by the REGgamma proteasome. Cell 2006; 124: 381-392.
10. Moriishi K, Okabayashi T, Nakai K, Moriya K, Koike K, Murata S, et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol 2003; 77: 10237-10249.
11. Nie J, Wu M, Wang J, Xing G, He F, Zhang L. REGgamma proteasome mediates degradation of the ubiquitin ligase Smurf1. FEBS Lett 2010; 584: 3021-3027.
12. Cioce M, Boulon S, Matera AG, Lamond AL. UV-induced fragmentation of Cajal bodies. J Cell Biol 2006; 175: 401-413.
13. Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, et al. A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell 2008; 19: 1706-1716.
14. Okamura T, Taniguchi S, Ohkura T, Yoshida A, Shimizu H, Sakai M, et al. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J Clin Endocrinol Metab 2003; 88: 1374-1383.
15. Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics 2006: 5: 2092-2101.
16. Pilotti S, Collini P, Manzari A, Marubini E, Rilke F. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol 1995; 12: 249-255.
17. Burman KD, Ringel MD, Wartofsky L. Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am 1996; 25: 49-68.
18. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol 2004; 86: 44-54.
19. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 2002; 161: 1549-1556.
20. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell 2007; 26: 831-842.
21. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
22. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154: 313-323.
23. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell 2007; 26: 843-852.
24. Masson P, Lundgren J, Young P. Drosophila proteasome regulator REGgamma: transcriptional activation by DNA replication-related factor DREF and evidence for a role in cell cycle progression. J Mol Biol 2003; 327: 1001-1012.
25. Murata S, Kawahara H, Tohma S, Yamamoto K, Kasahara M, Nabeshima Y, et al. Growth retardation in mice lacking the proteasome activator PA28gamma. J Biol Chem 1999; 274: 38211-38215.
26. Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, et al. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol 2004; 172: 3948-3954.
27. Tian M, Xiaoyi W, Xiaotao L, Guosheng R. Proteasomes reactivator REG gamma enchances oncogenicity of MDA-MB-231 cell line via promoting cell proliferation and inhibiting apoptosis. Cell Mol Biol 2009; 55 (Suppl): OL1121-OL1131.
28. Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 2002; 13: 453-464.
29. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995; 374: 386-388.
30. Chen J, Peters R, Saha P, Lee P, Theodoras A, Pagano M, et al. A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res 1996; 24: 1727-1733.
31. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995; 375: 159-161.
32. Goubin F, Ducommun B. Identification of binding domains on the p21 Cip1 cyclin-dependent kinase inhibitor. Oncogene 1995: 10: 2281-2287.
33. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
34. Bravo R, Frank R, Blundell PA, Donald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326: 515-517.
35. Prelich G, Tan CK, Kostura M, Mathews MB, So AG, Downey KM, et al. Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 1987; 326: 517-520.
36. Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121: 2228-2234.
37. Nikaido T, Shimada K, Shibata M, Hata M, Sakamoto M, Takasaki Y, et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus. Clin Exp Immunol 1990; 79: 209-214.
38. Engel FB, Hauck L, Boehm M, Nabel EG, Dietz R, von Harsdorf R. p21(CIP1) Controls proliferating cell nuclear antigen level in adult cardiomyocytes. Mol Cell Biol 2003; 23: 555-565.